%0 Journal Article
%T The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
%A Bertrand Routy
%A Guido Kroemer
%A Laurence Zitvogel
%A Lisa Derosa
%J Archive of "Oncoimmunology".
%D 2018
%R 10.1080/2162402X.2018.1434468
%X Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy
%K Microbiota
%K immune checkpoint blockers
%K PD-1/PD-L1
%K NSCLC
%K RCC
%K Biomarkers
%K Inflammation and cancer
%K New target
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980343/